These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 26351647)

  • 1. Meningococcal B Vaccination (4CMenB) in Infants and Toddlers.
    Esposito S; Tagliabue C; Bosis S
    J Immunol Res; 2015; 2015():402381. PubMed ID: 26351647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neisseria meningitidis serogroup B vaccine development.
    Caesar NM; Myers KA; Fan X
    Microb Pathog; 2013 Apr; 57():33-40. PubMed ID: 23416222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meningococcal B vaccine (4CMenB): the journey from research to real world experience.
    Rappuoli R; Pizza M; Masignani V; Vadivelu K
    Expert Rev Vaccines; 2018 Dec; 17(12):1111-1121. PubMed ID: 30457407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects.
    Mameli C; Galli E; Mantegazza C; Fabiano V; Zuccotti GV
    Future Microbiol; 2015; 10(10):1579-98. PubMed ID: 26437903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances towards the prevention of meningococcal B disease: a multidimensional story.
    Roderick M; Finn A
    J Infect; 2014 Jan; 68 Suppl 1():S76-82. PubMed ID: 24139188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).
    Gandhi A; Balmer P; York LJ
    Postgrad Med; 2016 Aug; 128(6):548-56. PubMed ID: 27467048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of a multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) for bacterial meningitis prevention.
    Esposito S; Castellazzi L; Bosco A; Musio A; Stoddard J
    Immunotherapy; 2014; 6(4):395-408. PubMed ID: 24815780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).
    Bettinger JA; Scheifele DW; Halperin SA; Vaudry W; Findlow J; Borrow R; Medini D; Tsang R;
    Vaccine; 2013 Dec; 32(1):124-30. PubMed ID: 23588089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Update on Meningococcal Vaccination.
    Garland JM
    R I Med J (2013); 2020 Aug; 103(6):41-43. PubMed ID: 32752565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the population-level impact of MenB vaccination via modeling: Potential for serogroup replacement.
    Hogea C; Van Effelterre T; Vyse A
    Hum Vaccin Immunother; 2016; 12(2):451-66. PubMed ID: 26308796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Will booster doses be required for serogroup B meningococcal vaccine?
    McQuaid F; Snape MD
    Expert Rev Vaccines; 2014 Mar; 13(3):313-5. PubMed ID: 24451002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine.
    Esposito S; Principi N
    Expert Rev Vaccines; 2014 Feb; 13(2):193-202. PubMed ID: 24393061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quadrivalent meningococcal conjugate vaccines.
    Pace D; Pollard AJ; Messonier NE
    Vaccine; 2009 Jun; 27 Suppl 2():B30-41. PubMed ID: 19477560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II meningococcal B vesicle vaccine trial in New Zealand infants.
    Jackson C; Lennon DR; Sotutu VT; Yan J; Stewart JM; Reid S; Crengle S; Oster P; Ypma E; Aaberge I; Mulholland K; Martin DR
    Arch Dis Child; 2009 Oct; 94(10):745-51. PubMed ID: 18838420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A combined approach to assess the potential coverage of a multicomponent protein-based vaccine.
    Boccadifuoco G; Brunelli B; Pizza MG; Giuliani MM
    J Prev Med Hyg; 2012 Jun; 53(2):56-60. PubMed ID: 23240161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine.
    Perez JL; Absalon J; Beeslaar J; Balmer P; Jansen KU; Jones TR; Harris S; York LJ; Jiang Q; Radley D; Anderson AS; Crowther G; Eiden JJ
    Expert Rev Vaccines; 2018 Jun; 17(6):461-477. PubMed ID: 29883226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neisseria meningitidis B vaccines.
    Panatto D; Amicizia D; Lai PL; Gasparini R
    Expert Rev Vaccines; 2011 Sep; 10(9):1337-51. PubMed ID: 21919622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.
    Santolaya ME; O'Ryan ML; Valenzuela MT; Prado V; Vergara R; Muñoz A; Toneatto D; Graña G; Wang H; Clemens R; Dull PM;
    Lancet; 2012 Feb; 379(9816):617-24. PubMed ID: 22260988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults.
    Toneatto D; Oster P; deBoer AC; Emerson A; Santos GF; Ypma E; DeTora L; Pizza M; Kimura A; Dull P
    Hum Vaccin; 2011 Jul; 7(7):781-91. PubMed ID: 21734467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease.
    Zlotnick GW; Jones TR; Liberator P; Hao L; Harris S; McNeil LK; Zhu D; Perez J; Eiden J; Jansen KU; Anderson AS
    Hum Vaccin Immunother; 2015; 11(1):5-13. PubMed ID: 25483509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.